BridgeBio (BBIO): Insider Notice to Sell 120,000 Shares ($6.51M)

BridgeBio Pharma, Inc. form 144 shows a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be executed approximately on 10/08/2025 on NASDAQ.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. form 144 shows a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be executed approximately on 10/08/2025 on NASDAQ. The shares were acquired on 03/26/2016 via conversion of Management Incentive Units. The filing lists the total shares outstanding as 191,168,504. Recent disclosed transactions show multiple 10b5-1 sales by related trusts and an individual (including Kumar Haldea Revocable/Family Trusts and Neil Kumar) across 08/07/2025–09/05/2025, totaling 186,156 shares sold in the past three months. The filer certifies no undisclosed material adverse information and notes the 10b5-1 representation where applicable.

Positive

• None.

Negative

• Proposed sale of 120,000 shares valued at $6,506,400 (planned 10/08/2025)
• Recent 10b5-1 sales total 186,156 shares across 08/07/2025–09/05/2025, indicating ongoing insider liquidity
• Shares represent insider-converted incentive units acquired on 03/26/2016, reducing insider-held restricted stake

Insights

Insider Transaction Analyst

TL;DR: A scheduled insider sale of 120,000 shares (~$6.5M) and recent 10b5-1 activity indicate ongoing planned liquidity by related parties.

The notice reports a proposed sale of $6,506,400 for 120,000 common shares with an approximate trade date of 10/08/2025. The shares were acquired by conversion of incentive units on 03/26/2016, which indicates these are long-held insider-originated securities.

Recent entries document multiple 10b5-1 sales by named trusts and an individual between 08/07/2025 and 09/05/2025, totaling 186,156 shares sold in the last three months. Monitor ongoing scheduled plan executions for additional supply pressure over the near term (weeks to months).

FAQ

What does the Form 144 for BridgeBio (BBIO) disclose?

The form discloses a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be sold around 10/08/2025 on NASDAQ.

Who acquired the shares being sold and when?

The shares were acquired on 03/26/2016 by conversion of Management Incentive Units from the issuer; the filer lists the acquisition date and nature as conversion.

Have related insiders recently sold BBIO shares?

Yes. The filing lists multiple 10b5-1 sales by Kumar Haldea Revocable Trust, Kumar Haldea Family Irrevocable Trust, and Neil Kumar between 08/07/2025 and 09/05/2025, totaling 186,156 shares.

How many BBIO shares are outstanding per the filing?

The filing reports 191,168,504 shares outstanding.

Does the filer state any undisclosed material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed and notes applicability of any 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/08/2025 - 04:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001742485
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BridgeBio Pharma, Inc.
SEC File Number	001-38959
Address of Issuer	3160 PORTER DRIVE SUITE 250 Palo Alto CALIFORNIA 94304
Phone	6503919740
Name of Person for Whose Account the Securities are To Be Sold	KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	120000	6506400.00	191168504	10/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/26/2016	Conversion Management Incentive Units	Issuer			120000	03/26/2016	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/05/2025	20000	1061044.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/05/2025	20000	1061002.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/04/2025	20000	1026862.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/04/2025	20000	1026926.00
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/20/2025	26156	1276925.46
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00

144: Remarks and Signature

Remarks
Date of Notice	10/08/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Neil Kumar
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)